

CITATION REPORT

List of articles citing

Policies for biosimilar uptake in Europe: An overview

DOI: 10.1371/journal.pone.0190147
PLoS ONE, 2017, 12, e0190147.

Source: <https://exaly.com/paper-pdf/87051435/citation-report.pdf>

Version: 2024-04-24

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
138	Clinical and Financial Implications of Medicine Consumption Patterns at a Leading Referral Hospital in Kenya to Guide Future Planning of Care. <i>Frontiers in Pharmacology</i> , 2018 , 9, 1348	5.6	6
137	Barriers for Access to New Medicines: Searching for the Balance Between Rising Costs and Limited Budgets. 2018 , 6, 328		68
136	Comparative Price Analysis of Biological Products for Treatment of Rheumatoid Arthritis. <i>Frontiers in Pharmacology</i> , 2018 , 9, 1070	5.6	24
135	Concepts and Challenges of Biosimilars in Breast Cancer: The Emergence of Trastuzumab Biosimilars. 2018 , 10,		8
134	Similar or the Same? Why Biosimilars are not the Solution. 2018 , 46, 776-790		6
133	Friction in the Path to Use of Biosimilar Drugs. 2018 , 378, 2148		3
132	An Overview of the Reimbursement Decision-Making Processes in Bulgaria As a Reference Country for the Middle-Income European Countries. 2018 , 6, 61		4
131	Comparative Analysis of Legislative Requirements About Patients' Access to Biotechnological Drugs for Rare Diseases in Central and Eastern European Countries. <i>Frontiers in Pharmacology</i> , 2018 , 9, 795	5.6	10
130	Projecting Pharmaceutical Expenditure in EU5 to 2021: Adjusting for the Impact of Discounts and Rebates. 2018 , 16, 803-817		10
129	Immunosuppressants in Brazil: underlying drivers of spending trends, 2010-2015. 2018 , 18, 565-572		4
128	Medicine Shortages: Gaps Between Countries and Global Perspectives. <i>Frontiers in Pharmacology</i> , 2019 , 10, 763	5.6	35
127	Costs associated with non-medical switching from originator to biosimilar etanercept in patients with rheumatoid arthritis in the UK. 2019 , 22, 1162-1170		9
126	Origins and Evolution of Drug Regulation. 2019 , 17-52		
125	Real-World Evidence on Etanercept Biosimilar SB4 in Etanercept-Naïve or Switching Patients: A Systematic Review. 2019 , 6, 317-338		9
124	Biosimilars in dermatology: The wind of change. 2019 , 18, 911-915		5
123	A Hybrid MCDM Model for Evaluating Strategic Alliance Partners in the Green Biopharmaceutical Industry. 2019 , 11, 4065		17
122	Biosimilars in rheumatology. 2019 , 149, 104467		2

121	The impact of implemented regulations on biosimilars in Slovakia. 2019 , 8, 408-413		2
120	Biosimilars in the USA: Will New Efforts to Spur Approvals and Access Spur Uptake and Cost Savings?. 2019 , 33, 1-8		4
119	Regulatory and Clinical Perspective on Biosimilars: a Comparison of the US and European Experiences. 2019 , 7, 111-117		2
118	Tracking the price of existing biologics when drugs enter the market. 2019 , 19, 375-377		4
117	Budget Impact of Switching to Biosimilar Trastuzumab (CT-P6) for the Treatment of Breast Cancer and Gastric Cancer in 28 European Countries. <i>BioDrugs</i> , 2019 , 33, 423-436	7.9	12
116	Switching to biosimilars: current perspectives in immune-mediated inflammatory diseases. <i>Expert Opinion on Biological Therapy</i> , 2019 , 19, 1001-1014	5.4	12
115	Biosimilars: An Approach to some Current Worldwide Regulation Frameworks. 2019 , 14, 16-40		2
114	Biological Therapies in Immune-Mediated Inflammatory Diseases: Can Biosimilars Reduce Access Inequities?. <i>Frontiers in Pharmacology</i> , 2019 , 10, 279	5.6	57
113	Sustainability in the biopharmaceutical industry: Seeking a holistic perspective. 2019 , 37, 698-707		14
112	Different Policy Measures and Practices between Swedish Counties Influence Market Dynamics: Part 1-Biosimilar and Originator Infliximab in the Hospital Setting. <i>BioDrugs</i> , 2019 , 33, 285-297	7.9	17
111	Recommendations for Lowering Prescription Drug Spending in Public Programs. 2019 , 171, 855-856		
110	Medication safety risks to be managed in national implementation of automatic substitution of biological medicines: a qualitative study. 2019 , 9, e032892		5
109	Breast Cancer: Reimbursement Policies and Adoption of New Therapeutic Agents by National Health Systems. 2019 , 14, 373-381		4
108	Observational study of inflammatory arthritis treatment by etanercept originator switched to an etanercept biosimilar. 2019 , 57, 257-263		7
107	The Clinical Implications of Nocebo Effects for Biosimilar Therapy. <i>Frontiers in Pharmacology</i> , 2019 , 10, 1372	5.6	30
106	Pharmacotherapeutic interventions for bipolar disorder type II: addressing multiple symptoms and approaches with a particular emphasis on strategies in lower and middle-income countries. 2019 , 20, 2237-2255		20
105	How to solve financing gap to ensure patient access to patented pharmaceuticals in CEE countries? - the good, the bad, and the ugly ways. 2019 , 19, 627-632		6
104	Drug Discontinuation in Studies Including a Switch From an Originator to a Biosimilar Monoclonal Antibody: A Systematic Literature Review. 2019 , 41, 155-173.e13		16

103	[Biosimilars in Internal Medicine: Needed in-depth knowledge to best prescribe]. 2019 , 40, 1-4		
102	Impact of a medical interview on the decision to switch from originator infliximab to its biosimilar in patients with inflammatory bowel disease. 2020 , 52, 281-288		8
101	Time to Review Authorisation and Funding for New Cancer Medicines in Europe? Inferences from the Case of Olaratumab. 2020 , 18, 5-16		18
100	Clinical evidence supporting the marketing authorization of biosimilars in Europe. 2020 , 76, 557-566		5
99	Tendering and biosimilars: what role for value-added services?. 2020 , 8, 1705120		8
98	Ongoing strategies to improve the management of upper respiratory tract infections and reduce inappropriate antibiotic use particularly among lower and middle-income countries: findings and implications for the future. 2020 , 36, 301-327		64
97	Identifying Key Benefits in European Off-Patent Biologics and Biosimilar Markets: It is Not Only About Price!. <i>BioDrugs</i> , 2020 , 34, 159-170	7.9	33
96	Uptake of Biosimilar Infliximab in the UK, France, Japan, and Korea: Budget Savings or Market Expansion Across Countries?. <i>Frontiers in Pharmacology</i> , 2020 , 11, 970	5.6	15
95	Sustainability of Biosimilars in Europe: A Delphi Panel Consensus with Systematic Literature Review. 2020 , 13,		1
94	Integrative Review of Managed Entry Agreements: Chances and Limitations. 2020 , 38, 1165-1185		12
93	Barriers to biosimilar utilization in the United States. 2020 , 77, 2006-2014		2
92	Learnings from Regional Market Dynamics of Originator and Biosimilar Infliximab and Etanercept in Germany. 2020 , 13,		6
91	Potential Cost-Savings From the Use of the Biosimilars in Slovakia. 2020 , 8, 431		5
90	Response to the Novel Corona Virus (COVID-19) Pandemic Across Africa: Successes, Challenges, and Implications for the Future. <i>Frontiers in Pharmacology</i> , 2020 , 11, 1205	5.6	68
89	Key patient related factors in the management of inflammatory bowel disease. 2020 , 23, 1606-1609		1
88	Fixed dose drug combinations - are they pharmaco-economically sound? Findings and implications especially for lower- and middle-income countries. 2020 , 20, 1-26		33
87	Physicians' perceptions of the uptake of biosimilars: a systematic review. 2020 , 10, e034183		25
86	Biosimilar Drug Development. 2020 , 1-24		

85	Ongoing and planned activities to improve the management of patients with Type 1 diabetes across Africa; implications for the future. 2020 , 48, 51-67		17
84	Mapping of Current Obstacles for Rationalizing Use of Medicines (CORUM) in Europe: Current Situation and Potential Solutions. <i>Frontiers in Pharmacology</i> , 2020 , 11, 144	5.6	11
83	Physician-Level Cost Control Measures and Regional Variation of Biosimilar Utilization in Germany. 2020 , 17,		2
82	Biosimilar drugs: Measures to promote their use. 2020 , 154, 148		
81	Review of Ongoing Activities and Challenges to Improve the Care of Patients With Type 2 Diabetes Across Africa and the Implications for the Future. <i>Frontiers in Pharmacology</i> , 2020 , 11, 108	5.6	43
80	Effective tools to manage biosimilars prescription: The Italian experience. 2021 , 10, 45-51		0
79	A Look at the History of Biosimilar Adoption: Characteristics of Early and Late Adopters of Infliximab and Etanercept Biosimilars in Subregions of England, Scotland and Wales - A Mixed Methods Study. <i>BioDrugs</i> , 2021 , 35, 75-87	7.9	1
78	A health economic guide to market access of biosimilars. <i>Expert Opinion on Biological Therapy</i> , 2021 , 21, 9-17	5.4	6
77	Did the Introduction of Biosimilars Influence Their Prices and Utilization? The Case of Biologic Disease Modifying Antirheumatic Drugs (bDMARD) in Bulgaria. 2021 , 14,		3
76	Availability and accessibility of monoclonal antibodies in Bosnia and Herzegovina: Findings and implications. 2021 , 5, 239920262110276		3
75	Changes in Availability, Utilization, and Prices of Medicines and Protection Equipment for COVID-19 in an Urban Population of Northern Nigeria. 2021 , 10, 17-22		7
74	Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice. 2021 , 124, 1346-1352		5
73	Use of budget savings from patent expiration of cancer drugs to improve affordability and accessibility. 2021 , 21, 126		
72	Informing Patients about Biosimilar Medicines: The Role of European Patient Associations. 2021 , 14,		9
71	Uptake of biosimilars for TNF- α inhibitors adalimumab and etanercept following the best-value biological medicine initiative in Ireland. 2021 , 43, 1251-1256		4
70	The pharmacoeconomic impact of follitropin alpha biosimilars in IVF therapy in Europe: a report of the literature. 2021 , 21, 553-558		3
69	Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications. 2021 , 21, 527-540		11
68	Barriers to Biosimilar Prescribing Incentives in the Context of Clinical Governance in Spain. 2021 , 14,		2

67	Effect of listing strategies on utilization of antitumor necrosis factor biologics infliximab and etanercept: a cross-sectional analysis from Ontario, Canada. 2021 , 27, 444-452		
66	Evolving Biosimilar Clinical Requirements: A Qualitative Interview Study with Industry Experts and European National Medicines Agency Regulators. <i>BioDrugs</i> , 2021 , 35, 351-361	7.9	
65	Prescribers' knowledge of drug costs: a contemporary Irish study. 2021 , 37, 272-281		
64	Does Similarity Breed Contempt? A Review of the Use of Biosimilars in Inflammatory Bowel Disease. 2021 , 66, 2513-2532		3
63	Policies to Encourage the Use of Biosimilars in European Countries and Their Potential Impact on Pharmaceutical Expenditure. <i>Frontiers in Pharmacology</i> , 2021 , 12, 625296	5.6	8
62	Strategies to Improve Antimicrobial Utilization with a Special Focus on Developing Countries. 2021 , 11,		23
61	The Current Situation Regarding Long-Acting Insulin Analogues Including Biosimilars Among African, Asian, European, and South American Countries; Findings and Implications for the Future. 2021 , 9, 671961		9
60	Biosimilar Insulins and Their Impact on Prices and Utilization of Insulins in Bulgaria. <i>Healthcare (Switzerland)</i> , 2021 , 9,	3.4	
59	Anti-TNF and immunosuppressive combination therapy is preferential to inducing clinical remission in patients with active inflammatory bowel disease: A systemic review and meta-analysis. 2021 , 22, 408-418		1
58	Current utilization patterns for long-acting insulin analogues including biosimilars among selected Asian countries and the implications for the future. 2021 , 37, 1529-1545		3
57	How Do Hospital Pharmacists Approach Substitution of Nanomedicines? Insights from a Qualitative Pilot Study and a Quantitative Market Research Analysis in Five European Countries. 2021 , 13,		
56	Is There Any Research Evidence Beyond Surveys and Opinion Polls on Automatic Substitution of Biological Medicines? A Systematic Review. <i>BioDrugs</i> , 2021 , 35, 547-561	7.9	0
55	Evidence-based public policy making for medicines across countries: findings and implications for the future. 2021 , 10, 1019-1052		7
54	Infliximab use in the Netherlands: Uptake and characteristics of originator and biosimilars over time. 2021 ,		0
53	Utilisation, Availability and Price Changes of Medicines and Protection Equipment for COVID-19 Among Selected Regions in India: Findings and Implications. <i>Frontiers in Pharmacology</i> , 2020 , 11, 582154	5.6	17
52	Rapid Assessment of the Potential Paucity and Price Increases for Suggested Medicines and Protection Equipment for COVID-19 Across Developing Countries With a Particular Focus on Africa and the Implications. <i>Frontiers in Pharmacology</i> , 2020 , 11, 588106	5.6	20
51	The Expiry of Humira Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures. <i>Frontiers in Pharmacology</i> , 2020 , 11, 591134	5.6	21
50	Biosimilars in Deutschland und im europäischen Vergleich [Entwicklungen und Potenziale. 2019 , 321-353		4

49	Switching to biosimilars in the treatment of rheumatic diseases. 2018 , 14, 557-571		4
48	Biosimilars: Exploring the History, Science, and Progress. 2018 , 22, 5-12		3
47	Rapid Assessment of Price Instability and Paucity of Medicines and Protection for COVID-19 Across Asia: Findings and Public Health Implications for the Future. 2020 , 8, 585832		32
46	Strategic Deterrence: An Application to Biologic Pharmaceuticals.		
45	Biologika und Biosimilars. 2019 , 177-212		
44	Biosimilars in Deutschland und im europäischen Vergleich [Marktsteuerungsmechanismen und Einsparpotenziale. 2020 , 201-225		3
43	Biosimilar drugs: Measures to promote their use. 2020 , 154, 148		0
42	Optimizing Use of Biologic Medicines Using a Quality Use of Medicines Approach. 2020 , 237-251		
41	Pharmacoeconomics of Biologic Medicines and Biosimilars. 2020 , 195-212		1
40	Greater uptake, an alternative reimbursement methodology needed to realize cost-saving potential of oncology biosimilars in the United States. 2021 , 27, 1642-1651		0
39	[Interchangeability and substitution of biosimilars]. 2020 , 78, 277-284		0
38	Biosimilar Drugs and the Hospital Formulary: A Canadian Experience. <i>Canadian Journal of Hospital Pharmacy</i> , 2019 , 72, 145-150	0.5	3
37	Assessing Knowledge and Attitude of Healthcare Professionals on Biosimilars: A National Survey for Pharmacists and Physicians in Taiwan. <i>Healthcare (Switzerland)</i> , 2021 , 9,	3.4	0
36	Biologika und Biosimilars in Deutschland und im europäischen Vergleich □ Marktsteuerungsmechanismen und Preisvergleich. 2021 , 75-107		2
35	Volume and trends of adalimumab and pembrolizumab reimbursed market: the Bulgarian perspective. <i>Biotechnology and Biotechnological Equipment</i> , 2021 , 35, 1778-1791	1.6	
34	Projected impact of biosimilar substitution policies on drug use and costs in Ontario, Canada: a cross-sectional time series analysis. <i>CMAJ Open</i> , 2021 , 9, E1055-E1062	2.5	2
33	Qualitative Analysis of the Design and Implementation of Benefit-Sharing Programs for Biologics Across Europe.. <i>BioDrugs</i> , 2022 , 36, 217	7.9	1
32	Penetration rate of anti-TNF biosimilars and savings at 5 years after their introduction in French hospitals.. <i>Therapie</i> , 2021 ,	3.8	0

31	The Coming of Age of Biosimilars: A Personal Perspective. <i>Biologics</i> , 2022 , 2, 107-127		1
30	Table_1.DOCX. 2018 ,		
29	Table_2.DOCX. 2018 ,		
28	DataSheet_1.docx. 2020 ,		
27	Table_1.DOCX. 2019 ,		
26	DataSheet_1.pdf. 2019 ,		
25	Dynamics of biosimilar uptake in emerging markets.. <i>Expert Opinion on Biological Therapy</i> , 2022 ,	5.4	0
24	The Effect of Biosimilar Prescription Targets for Erythropoiesis-Stimulating Agents on the Prescribing Behavior of Physicians in Germany.. <i>Value in Health</i> , 2022 ,	3.3	0
23	Challenges and Opportunities With Routinely Collected Data on the Utilization of Cancer Medicines. Perspectives From Health Authority Personnel Across 18 European Countries. <i>Frontiers in Pharmacology</i> , 13,	5.6	2
22	Perspectives toward biosimilars among oncologists: A Malaysian survey. <i>Journal of Oncology Pharmacy Practice</i> , 107815522211047	1.7	0
21	Biosimilars in Pediatric IBD: Updated Considerations for Disease Management. <i>Biologics: Targets and Therapy</i> , Volume 16, 57-66	4.4	0
20	The Price and Market Share Evolution of the Original Biologics and Their Biosimilars in Finland. <i>BioDrugs</i> , 2022 , 36, 537-547	7.9	0
19	Pharmacists' Perspectives of Biosimilars: A Systematic Review. <i>BioDrugs</i> , 2022 , 36, 489-508	7.9	1
18	Assessing, Pricing and Funding Point-of-Care Diagnostic Tests for Community-Acquired Acute Respiratory Tract Infections: Overview of Policies Applied in 17 European Countries. 2022 , 11, 987		
17	Switching Among Biosimilars: A Review of Clinical Evidence. 13,		1
16	Adalimumab biosimilars in the therapy of Crohn's disease and ulcerative colitis: Prospective multicentric clinical monitoring. 2022 , 17, e0271299		1
15	Systematic Review on the Use of Biosimilars of Trastuzumab in HER2+ Breast Cancer. 2022 , 10, 2045		0
14	Applications of Behavioral Economics to Pharmaceutical Policymaking: A Scoping Review with Implications for Best-Value Biological Medicines.		

- 13 The whole experience of public hospital physicians from several specialties with biopharmaceutical effectiveness, safety, adverse drug reactions and interchangeability: A qualitative study. **2022**, 7, 100162
- 12 Biosimilar Drug Development. **2022**, 1237-1260 ○
- 11 Current Expertise, Opinions, and Attitude toward TNF- α Antagonist Biosimilars among Physicians: A Self-Administered Online Survey in Western Switzerland. **2022**, 10, 2152 ○
- 10 How do hospital characteristics and ties relate to the uptake of second-generation biosimilars? A longitudinal analysis of Portuguese NHS hospitals, 2015-2021. ○
- 9 TNF-alpha inhibitors biosimilar use in France: a nationwide population-based study using the French National Health Data System. **2022**, 12, ○
- 8 Malaysian Hospital Pharmacists' Perspectives and Their Role in Promoting Biosimilar Prescribing: A Nationwide Survey. ○
- 7 Factors associated with the uptake of biosimilars for breast cancer treatment from the perspectives of physicians and patients-Evidence from China. 13, ○
- 6 Überblick über Maßnahmen zur Förderung des Einsatzes von Biosimilars in europäischen Ländern. **2022**, 57-81 ○
- 5 Recommendations on TNF α inhibitor biosimilar use in clinical practice: a comparison of European gastroenterology IBD guidance. 1-17 ○
- 4 Market diffusion of biosimilars in off-patent biologic drug markets across Europe. **2023**, 132, 104818 ○
- 3 Tackling reimbursement challenges to fair access to medicines Introduction to the topic. 1-10 ○
- 2 Biosimilar competition in European markets of TNF-alpha inhibitors: a comparative analysis of pricing, market share and utilization trends. 14, ○
- 1 Intercambialidade e aspectos farmacoeconómicos dos medicamentos biossimilares. 15, ○